Dainippon Sumitomo Pharma Europe Ltd ("DSPE") (Headquarters: London, UK) today announced that the European Medicines Agency (EMA) has confirmed that the Marketing Authorisation Application (MAA) for lurasidone hydrochloride, an atypical antipsychotic investigational medicine for the treatment of schizophrenia, is valid...